You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Deerfield Mgmt | 0 | 347,100 | 0 | 347,100 | 347,100 | 2.07% |
Deerfield Management Company | 0 | 1,224,899 | 0 | 1,224,899 | 1,224,899 | 7.30% |
Deerfield Mgmt III | 0 | 877,799 | 0 | 877,799 | 877,799 | 5.23% |
Deerfield Special Situations Fund | 0 | 149,676 | 0 | 149,676 | 149,676 | 0.89% |
Deerfield Partners | 0 | 86,867 | 0 | 86,867 | 86,867 | 0.52% |
Deerfield International Master Fund | 0 | 110,557 | 0 | 110,557 | 110,557 | 0.66% |
Deerfield Private Design Fund III | 0 | 877,799 | 0 | 877,799 | 877,799 | 5.23% |
James E. Flynn | 0 | 1,224,899 | 0 | 1,224,899 | 1,224,899 | 7.30% |
Page 1 of 19 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS
THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. 4) *
Proteon Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
74371L109
(CUSIP Number)
May 1, 2017
(Date of Event Which Requires Filing of
this Statement)
Check the appropriate box to designate the
rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
(Page 1 of 15 Pages)
———-
* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 2 of 19 – SEC Filing
CUSIP No. | 74371L109 | 13G | Page 2 of 15 Pages |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Mgmt, L.P. | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 347,100 (1) | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 347,100 (1) | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 347,100 (1) | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.07% | ||
12. | TYPE OF REPORTING PERSON* PN |
__________________
(1) Comprised of shares of common stock held by Deerfield Special Situations Fund, L.P., Deerfield Partners,
L.P. and Deerfield International Master Fund, L.P., of which Deerfield Mgmt, L.P. is the general partner.
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 3 of 19 – SEC Filing
CUSIP No. | 74371L109 | 13G | Page 3 of 15 Pages |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Management Company, L.P. | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 1,224,899 (2) | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 1,224,899 (2) | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,224,899 (2) | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 7.30% | ||
12. | TYPE OF REPORTING PERSON* PN |
__________________
(2) Comprised of shares of common stock held by Deerfield Private Design Fund III, L.P., Deerfield Special
Situations Fund, L.P., Deerfield Partners, L.P. and Deerfield International Master Fund, L.P., of which Deerfield Management Company,
L.P. is the investment advisor.
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 4 of 19 – SEC Filing
CUSIP No. | 74371L109 | 13G | Page 4 of 15 Pages |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Mgmt | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 877,799 (3) | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 877,799 (3) | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 877,799 (3) | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.23% | ||
12. | TYPE OF REPORTING PERSON* PN |
_________________
(3) Comprised of shares of common stock held by Deerfield Private Design Fund III, L.P., of which Deerfield
Mgmt III, L.P. is the general partner.
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 5 of 19 – SEC Filing
CUSIP No. | 74371L109 | 13G | Page 5 of 15 Pages |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Special | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 149,676 | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 149,676 | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 149,676 | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.89% | ||
12. | TYPE OF REPORTING PERSON* PN |
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 6 of 19 – SEC Filing
CUSIP No. | 74371L109 | 13G | Page 6 of 15 Pages |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Partners, L.P. | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 86,867 | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 86,867 | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 86,867 | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.52% | ||
12. | TYPE OF REPORTING PERSON* PN |
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 7 of 19 – SEC Filing
CUSIP No. | 74371L109 | 13G | Page 7 of 15 Pages |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield International Master Fund, L.P. | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 110,557 | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 110,557 | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 110,557 | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.66% | ||
12. | TYPE OF REPORTING PERSON* PN |
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 8 of 19 – SEC Filing
CUSIP No. | 74371L109 | 13G | Page 8 of 15 Pages |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Private Design Fund III, L.P. | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 877,799 | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 877,799 | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 877,799 | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.23% | ||
12. | TYPE OF REPORTING PERSON* PN |
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 9 of 19 – SEC Filing
CUSIP No. | 74371L109 | 13G | Page 9 of 15 Pages |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) James E. Flynn | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION United States | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 1,224,899 (4) | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 1,224,899 (4) | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,224,899 (4) | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 7.30% | ||
12. | TYPE OF REPORTING PERSON* IN |
__________________
(4) Comprised of shares of common stock held by Deerfield Private
Design Fund III, L.P., Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P. and Deerfield International Master Fund,
L.P.
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 10 of 19 – SEC Filing
CUSIP No. | 74371L109 | 13G | Page 10 of 15 Pages |
The sole purpose of this Amendment No. 4 to Schedule 13G is
to reflect the addition of Deerfield Partners, L.P. and Deerfield International Master Fund, L.P. as reporting persons.
Item 1(a). | Name of Issuer: | |
Proteon | ||
Item 1(b). | Address of Issuer’s Principal Executive Offices: | |
200 West Street Waltham, MA 02451 | ||
Item 2(a). | Name of Person Filing: | |
James | ||
Item 2(b). | Address of Principal Business Office, or if None, Residence: | |
James E. Flynn, Deerfield Mgmt, L.P., Deerfield | ||
Item 2(c). | Citizenship: | |
Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Deerfield International Master Fund, L.P. – James E. Flynn – United States citizen | ||
Item 2(d). | Title of Class of Securities: | |
Common Stock | ||
Item 2(e). | CUSIP Number: | |
74371L109 | ||
Item 3. | If This Statement is Filed Pursuant to | |
(a) | ☐ | Broker or dealer registered under Section 15 of the |
(b) | ☐ | Bank as defined in Section 3(a)(6) of the Exchange Act. |
(c) | ☐ | Insurance company as defined in Section 3(a)(19) of |
(d) | ☐ | Investment company registered under Section 8 of the |
(e) | ☐ | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); |
(f) | ☐ | An employee benefit plan or endowment fund in accordance |
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 11 of 19 – SEC Filing
CUSIP No. | 74371L109 | 13G | Page 11 of 15 Pages |
(g) | ☐ | A parent holding company or control person in accordance |
(h) | ☐ | A savings association as defined in Section 3(b) of |
(i) | ☐ | A church plan that is excluded from the definition |
(j) | ☐ | A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); |
(k) | ☐ | Group, in accordance with Rule 13d-1(b)(1)(ii)(K). |
If filing as a non-U.S. institution in accordance
with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________
Item 4. | Ownership. | ||
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. | |||
(a) | Amount beneficially owned**: | ||
Deerfield Mgmt, L.P. – 347,100 shares Deerfield Mgmt III, L.P. – 877,799 shares Deerfield Management Company, L.P. – 1,224,899 shares Deerfield Special Situations Fund, L.P. – 149,676 Deerfield Partners, L.P. – 86,867 shares Deerfield International Master Fund, L.P. – Deerfield Private Design Fund III, L.P. – James E. Flynn – 1,224,899 shares | |||
(b) | Percent of class**: | ||
Deerfield Mgmt, L.P. – 2.07% Deerfield Mgmt III, L.P. – 5.23% Deerfield Management Company, L.P. – 7.30% Deerfield Special Situations Fund, L.P. – Deerfield Partners, L.P. – 0.52% Deerfield International Master Fund, L.P. – Deerfield Private Design Fund III, L.P. – James E. Flynn – 7.30% | |||
(c) | Number of shares as to which such person has**: | ||
(i) | Sole power to vote or to direct the vote: | All Reporting Persons 0 | |
(ii) | Shared power to vote or to direct the vote: | Deerfield Mgmt, L.P. – 347,100 Deerfield Mgmt III, L.P. – 877,799 Deerfield Management Company, L.P. – 1,224,899 Deerfield Special Situations Fund, L.P. – 149,676 Deerfield Partners, L.P. – 86,867 Deerfield International Master Fund, L.P. – Deerfield Private Design Fund III, L.P. – 877,799 James E. Flynn – 1,224,899 | |
(iii) | Sole power to dispose or to direct the disposition of | All Reporting Persons – 0 | |
(iv) | Shared power to dispose or to direct the disposition | Deerfield Mgmt, L.P. – 347,100 Deerfield Mgmt III, L.P. – 877,799 Deerfield Management Company, L.P. – Deerfield Special Situations Fund, L.P. Deerfield Partners, L.P. – 86,867 Deerfield International Master Fund, Deerfield Private Design Fund III, L.P. James E. Flynn – 1,224,899 |
**See footnotes on cover pages which are incorporated by reference
herein.
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 12 of 19 – SEC Filing
CUSIP No. | 74371L109 | 13G | Page 12 of 15 Pages |
Item 5. | Ownership of Five Percent or Less of a Class. |
If this statement | |
Item 6. | Ownership of More Than Five Percent on Behalf of Another Person. |
If any other person | |
N/A | |
Item 7. | Identification and Classification of the Subsidiary |
If a parent holding | |
N/A | |
Item 8. | Identification and Classification of Members of the Group. |
If a group has filed | |
See Exhibit B | |
Item 9. | Notice of Dissolution of Group. |
Notice of dissolution | |
N/A |
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 13 of 19 – SEC Filing
CUSIP No. | 74371L109 | 13G | Page 13 of 15 Pages |
Item 10. | Certifications. |
“By signing below |
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 14 of 19 – SEC Filing
CUSIP No. | 74371L109 | 13G | Page 14 of 15 Pages |
SIGNATURE
After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
DEERFIELD MGMT, L.P.
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MANAGEMENT COMPANY, L.P.
By: Flynn Management LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MGMT III, L.P.
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD SPECIAL SITUATIONS FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PARTNERS, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD INTERNATIONAL MASTER FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PRIVATE DESIGN FUND III, L.P.
By: Deerfield Mgmt III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 15 of 19 – SEC Filing
CUSIP No. | 74371L109 | 13G | Page 15 of 15 Pages |
JAMES E. FLYNN
/s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
Date: May 2, 2017
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 16 of 19 – SEC Filing
Exhibit List
Exhibit A. Joint Filing Agreement.
Exhibit B. Item 8 Statement.
Exhibit C. Power of Attorney (1).
(1) Power of Attorney previously filed as Exhibit 24 to a Form
3 with regard to Editas Medicine, Inc. filed with the Securities and Exchange Commission on February 2, 2016 by Deerfield
Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt HIF, L.P., Deerfield
Private Design Fund III, L.P. and James E. Flynn.
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 17 of 19 – SEC Filing
Exhibit A
Joint Filing Agreement
The undersigned agree that this Schedule 13G, and all amendments
thereto, relating to the Common Stock of Proteon Therapeutics, Inc. shall be filed on behalf of the undersigned.
DEERFIELD MGMT, L.P.
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MANAGEMENT COMPANY, L.P.
By: Flynn Management LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MGMT III, L.P.
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD SPECIAL SITUATIONS FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PARTNERS, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD INTERNATIONAL MASTER FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PRIVATE DESIGN FUND III, L.P.
By: Deerfield Mgmt III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 18 of 19 – SEC Filing
JAMES E. FLYNN
/s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Follow Protara Therapeutics Inc. (NASDAQ:TARA)
Page 19 of 19 – SEC Filing
Exhibit B
Due to the relationships between them,
the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3)
of the Securities Exchange Act of 1934.